TALIS BIOMEDICAL CORP's ticker is TLIS and the CUSIP is 87424L108. A total of 48 filers reported holding TALIS BIOMEDICAL CORP in Q4 2021. The put-call ratio across all filers is 2.03 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $109,728 | +9.9% | 223,934 | 0.0% | 0.01% | +40.0% |
| Q4 2022 | $99,807 | -34.8% | 223,934 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $153,000 | -15.9% | 223,934 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $182,000 | -49.7% | 223,934 | -12.7% | 0.01% | -50.0% |
| Q1 2022 | $362,000 | -52.1% | 256,395 | +36.2% | 0.01% | -47.4% |
| Q4 2021 | $755,000 | +880.5% | 188,269 | +1426.1% | 0.02% | +850.0% |
| Q3 2021 | $77,000 | – | 12,337 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenlight Capital | 1,569,300 | $6,293,000 | 0.36% |
| ArrowMark Colorado Holdings LLC | 4,915,239 | $19,710,000 | 0.16% |
| Baker Brothers Advisors | 7,624,835 | $30,576,000 | 0.15% |
| Golden State Equity Partners | 22,133 | $89,000 | 0.04% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 188,269 | $755,000 | 0.02% |
| PDT Partners, LLC | 34,890 | $140,000 | 0.01% |
| PERSONAL CFO SOLUTIONS, LLC | 10,000 | $40,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 32,500 | $130,000 | 0.00% |
| Qube Research & Technologies Ltd | 59,161 | $237,000 | 0.00% |
| TWO SIGMA INVESTMENTS, LP | 78,628 | $315,000 | 0.00% |